Table 1.

Photodynamic therapy for chronic central serous chorioretinopathy

Authors	Number of eyes	Verteporfin dose (mg/m2)	PDT fluence (J/cm2)	Resolution of SRF (%)	VA improved (%)	VA unchanged (%)	VA worse (%)	Follow up (months)
Yannuzzi et al24	20	6	50	60	30	70	–	4–12.5
Taban et al26	5	6	50	100	80	20	–	8–12
Cardillo Piccolino et al25	16	6	50	81	69	31	–	6–12
Chan et al36	48	3	50	90	96		4	12
Shinojima et al40	17	3	50	94	6	6	88
Shin et al34	33	6	25	94	*	–	–	6–33
	34	6	50	100	**	–	–	5–25
Reibaldi et al31	23	6	25	91	***	–	–	12
	19	6	50	79	****	–	–	12
Silva et al47	48	6	50	93	74	17	9	48
Smretschnig et al35	20	6	25	100	92	8	–	1

Notes:

^*LogMAR change from baseline 0.34 to 0.17 after treatment;

^**LogMAR change from baseline 0.46 to 0.21 after treatment;

^***LogMAR change from baseline 0.46 to 0.16 after treatment;

^****LogMAR change from baseline 0.43 to 0.27 after treatment.

Abbreviations: LogMAR, logarithm of the minimum angle of resolution; PDT, photodynamic therapy; SRF, subretinal fluid; VA, visual acuity.